Effects of Ivabradine on Patients with Depressed

Cardiac resynchronization therapy (CRT) and ivabradine therapy are considered second-line therapies based on guideline recommendations, and therefore should be considered for suitable heart failure patients with reduced ejection fraction (HFrEF) after standard HF medical therapy

Effects of Ivabradine on Patients with Depressed Left Ventricular Function after Cardiac Resynchronization Therapy

The aim of this study was to evaluate the clinical effects of ivabradine in patients who received CRT implantation but who still had a left ventricular ejection fraction (LVEF) < 40% following successful CRT implantation.

After applying the inclusion and exclusion criteria, the patients were further classified into two groups. Group 1 patients had received ivabradine for at least six months after CRT implantation, and Group 2 patients did not receive ivabradine treatment throughout the study period.

Among the patients who received CRT therapy but who still had a LVEF < 40% and resting sinus rate 75 bpm, ivabradine treatment effectively reduced the heart rate and enhanced their physical activity. Furthermore, ivabradine treatment was well-tolerated and did not increase AF burden or affect biventricular pacing percentage in the HF patients.

Acta Cardiol Sin 2022;38:475484 doi: 10.6515/ACS.202207_38⁴.20211228B